News & Views
Financing to Initiate Clinical Trial in AML
Mar 27 2020
An additional €9M ($9.8M) financing from Xerys Funds is enabling Advanced BioDesign, dedicated to developing new therapies for overcoming tumour resistant cancers, to pursue its clinical development. It is the largest investment round since successive progressive fundraising operations initiated in 2013 totalled close to €7.5M ($8.1M), which has supported the company through its fundamental work on the mechanism of action for its lead compound ABD-3001 and consolidation of knowledge on its anti-cancer properties.
Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorisation to start clinical phase I in Acute Myeloid Leukemia (AML) in early 2021.
“We are delighted to have secured this new investment. It is a clear sign of support and confidence from our long-standing investor,” said Ismail Ceylan, CEO of Advanced BioDesign. “This new fundraising will allow us to reach our ambitions and initiate the First-in-Human administration of our lead-compound in acute myeloid leukemia.”
“ABD-3001 is a therapeutic innovation offering great potential for the treatment of the most challenging cancers,” said Olivier Ossipoff, Xerys chairman. “The preliminary results obtained from in vivo models of cancers with unmet medical needs are quite remarkable and promising for patients. This compound is particularly innovative and perfectly fits our investment criteria and our objectives in medical improvement.”
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK
May 21 2024 Lagos, Nigeria